Holen Sie sich die Stockscreener-App
1.7275
11.48%
-0.2325
Schlusskurs vom Vortag:
$1.96
Offen:
$1.94
24-Stunden-Volumen:
4.77M
Relative Volume:
0.95
Marktkapitalisierung:
$566.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-6.3981
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
-7.22%
1M Leistung:
+30.45%
6M Leistung:
+68.45%
1J Leistung:
+202.53%
1-Tages-Spanne:
$1.72
$1.96
1-Wochen-Bereich:
$1.66
$2.00
52-Wochen-Spanne:
$0.515
$2.00
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.73 | 641.55M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.11 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.98 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.91 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.83 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
OCGN Analyst Rating Maintained by Chardan Capital at Buy with $7 - GuruFocus
Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com Nigeria
Ocugen (OCGN) Advances Gene Therapy Trials and Strengthens Leade - GuruFocus
Ocugen (NASDAQ:OCGN) Shares Gap DownWhat's Next? - MarketBeat
Ocugen (OCGN) Reports Q4 Earnings and Cash Position Update - GuruFocus
Ocugen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - Ocugen, Inc.
Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M - TradingView
Ocugen (NASDAQ: OCGN) advances RP, GA and Stargardt gene therapies - Stock Titan
Ocugen Seeks Court Validation of Charter Amendment Dispute - TipRanks
Ocugen (NASDAQ:OCGN) Announces Earnings Results - MarketBeat
Court petition over Ocugen (NASDAQ: OCGN) share increase vote - Stock Titan
Ocugen (NASDAQ: OCGN) advances eye gene therapies and extends cash runway - Stock Titan
Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost - Traders Union
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com Nigeria
Ocugen Q4 Earnings Call Highlights - Yahoo Finance
OCGN: Advanced gene therapy pipeline, strong clinical data, and extended cash runway into late 2026 - TradingView
OCGN: OCU400 Phase 3 enrollment completed; strong pipeline progress and extended cash runway - TradingView
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ocugen (OCGN) Achieves Significant Milestones in 2025 - GuruFocus
OCUGEN ($OCGN) Releases Q4 2025 Earnings - Quiver Quantitative
OCGN: Advanced gene therapy pipeline and secured financing, extending cash runway into late 2026 - TradingView
Ocugen Completes Enrollment in OCU400 Phase 3 Clinical Trial for Retinitis Pigmentosa, Prepares for Major 2027 Data Announcements - Quiver Quantitative
Earnings Summary: Ocugen Q4 - Benzinga
BRIEF-Ocugen Q4 EPS USD -0.06 - TradingView
Gene therapy push for blindness: how Ocugen plans to fund it - Stock Titan
OCGN Earnings History & Surprises | EPS & Revenue Results | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen: Fourth Quarter Financial Results Overview - Bitget
Examining the Future: Ocugen's Earnings Outlook - Benzinga
OCGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighStill a Buy? - MarketBeat
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Key facts: Ocugen completes patient enrollment for OCU400 trial; 6-cent loss per share expected - TradingView
Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete - TipRanks
Ocugen completes enrollment in phase 3 retinitis pigmentosa trial - Investing.com
Ocugen Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Ocugen (OCGN) Completes Enrollment for Phase 3 OCU400 Trial - GuruFocus
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - Bitget
Ocugen, Inc. advances gene therapies for rare inherited retinal diseases amid global support - Traders Union
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharm - StreetInsider
Ocugen Advances Toward Key Regulatory Submission for Gene Therapy - AD HOC NEWS
How The Investment Story For Ocugen (OCGN) Is Shifting With New Data And Funding Moves - Yahoo Finance
Why Did OCGN Stock Rise Today? - Asianet Newsable
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):